Patents by Inventor Rolf Jautelat

Rolf Jautelat has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 6-THIO-SUBSTITUTED IMIDAZOPYRAZINES FOR USE AS MPS-1 AND TKK INHIBITORS IN THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS
    Publication number: 20130281460
    Abstract: The present invention relates to substituted imidazopyrazine compounds of general formula (I): (I) in which R1, R2, R3, R4 and R5 are as defined in the claims, to methods of and intermediates for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: December 13, 2011
    Publication date: October 24, 2013
    Applicant: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Marcus Koppitz, Ulrich Klar, Rolf Jautelat, Dirk Kosemund, Rolf Bohlmann, Benjamin Bader, Philip Lienau, Gerhard Siemeister
  • SUBSTITUTED 6-FLUORO-1H-PYRAZOLO[4,3-B]PYRIDINES AND USE THEREOF
    Publication number: 20130267548
    Abstract: The present application relates to novel substituted 6-fluoro-1H-pyrazolo[4,3-b]pyridines, to processes for preparation thereof, to the use thereof, alone or in combinations, for treatment and/or prophylaxis of diseases and to the use thereof for preparing Medicaments for the treatment and/or prophylaxis of diseases, especially for treatment and/or prophylaxis of cardiovascular disorders.
    Type: Application
    Filed: November 3, 2011
    Publication date: October 10, 2013
    Applicant: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Markus Follmann, Johannes-Peter Stasch, Gorden Redlich, Jens Ackerstaff, Nils Griebenow, Andreas Knorr, Frank Wunder, Volkhart Min-Jian Li, Joachim Mittendorf, Karl-Heinz Schlemmer, Rolf Jautelat
  • SUBSTITUTED 6-IMIDAZOPYRAZINES FOR USE AS MPS-1 AND TKK INHIBITORS IN THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS
    Publication number: 20130267527
    Abstract: The present invention relates to substituted imidazopyrazine compounds of general formula (I), in which R1, R2, R3, R4 and R5 are as defined in the claims, to methods of and intermediates for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: December 13, 2011
    Publication date: October 10, 2013
    Applicant: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Marcus Koppitz, Ulrich Klar, Rolf Jautelat, Dirk Kosemund, Rolf Bohlmann, Benjamin Bader, Philip Lienau, Gerhard Siemeister
  • SUBSTITUTED IMIDAZOPYRAZINES
    Publication number: 20130210815
    Abstract: The present invention relates to substituted imidazopyrazine compounds of general formula (I) in which A, R1, R3 and R5 are as given in the description and in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds, to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, as well as to intermediate compounds useful in the preparation of said compounds.
    Type: Application
    Filed: May 27, 2011
    Publication date: August 15, 2013
    Applicant: Bayer Intellectual Property GmbH
    Inventors: Ulrich Klar, Marcus Koppitz, Rolf Jautelat, Dirk Kosemund, Rolf Bohlmann, Benjamin Bader, Philip Lienau, Gerhard Siemeister, William Scott
  • Sulfoximine-substituted pyrimidines as CDK- and/or VEGF inhibitors, their production and use as pharmaceutical agents
    Patent number: 8507510
    Abstract: This invention relates to pyrimidine derivatives of general formula I in which Q, R1, R2, R3, R4, R5, X, and m have the meanings that are contained in the description, as inhibitors of cyclin-dependent kinases and VEGF-receptor tyrosine kinases, their production as well as their use as medications for treatment of various diseases.
    Type: Grant
    Filed: October 12, 2004
    Date of Patent: August 13, 2013
    Assignee: Bayer Intellectual Property GmbH
    Inventors: Ulrich Lücking, Martin Krüger, Rolf Jautelat, Gerhard Siemeister
  • Substituted 5-fluoro-1H-pyrazolopyridines and their use
    Patent number: 8420656
    Abstract: The present application relates to novel substituted 5-fluoro-1H-pyrazolopyridines, to processes for their preparation, to their use alone or in combinations for the treatment and/or prophylaxis of diseases, and to their use for producing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular disorders.
    Type: Grant
    Filed: May 19, 2011
    Date of Patent: April 16, 2013
    Assignee: Bayer Intellectual Property GmbH
    Inventors: Markus Follmann, Johannes-Peter Stasch, Gorden Redlich, Jens Ackerstaff, Nils Griebenow, Walter Kroh, Andreas Knorr, Eva-Maria Becker, Frank Wunder, Volkhart Min-Jian Li, Elke Hartmann, Joachim Mittendorf, Karl-Heinz Schlemmer, Rolf Jautelat, Donald Bierer
  • Substituted 5-fluoro-1H-pyrazolopyridines and their use
    Publication number: 20120022084
    Abstract: The present application relates to novel substituted 5-fluoro-1H-pyrazolopyridines, to processes for their preparation, to their use alone or in combinations for the treatment and/or prophylaxis of diseases, and to their use for producing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular disorders.
    Type: Application
    Filed: May 19, 2011
    Publication date: January 26, 2012
    Applicant: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT
    Inventors: Markus Follmann, Johannes-Peter Stasch, Gorden Redlich, Jens Ackerstaff, Nils Griebenow, Walter Kroh, Andreas Knorr, Eva-Maria Becker, Frank Wunder, Volkhart Min-Jian Li, Elke Hartmann, Joachim Mittendorf, Karl-Heinz Schlemmer, Rolf Jautelat, Donald Bierer
  • SULFOXIMINE-SUBSTITUTED ANILINOPYRIMIDINE DERIVATIVES AS CDK INHIBITORS, THE PRODUCTION THEREOF, AND USE AS MEDICINE
    Publication number: 20110294838
    Abstract: The invention relates to sulfoximine-substituted anilino-pyrimidine derivatives of formula (I). methods of production thereof, and use thereof as medication for the treatment of various diseases.
    Type: Application
    Filed: October 9, 2009
    Publication date: December 1, 2011
    Applicant: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT
    Inventors: Ulrich Lücking, Rolf Jautelat, Gerhard Siemeister, Julia Schulze, Philip Lienau
  • SULFONE-SUBSTITUTED ANILINOPYRIMIDINE DERIVATIVES AS CDK INHIBITORS, THE PRODUCTION THEREOF, AND USE AS A MEDICINE
    Publication number: 20110251222
    Abstract: The invention relates to sulphone-substituted anilinopyrimidine derivatives of the formula (I), to its preparation processes, and to its use as medicament for treating various diseases.
    Type: Application
    Filed: October 8, 2009
    Publication date: October 13, 2011
    Applicant: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT
    Inventors: Ulrich Lücking, Gerhard Siemeister, Philip Lienau, Rolf Jautelat, Julia Schulze
  • Sulphimides as protein kinase inhibitors
    Patent number: 7943629
    Abstract: The invention relates to sulphimides as protein kinase inhibitors of the general formula I
    Type: Grant
    Filed: June 7, 2007
    Date of Patent: May 17, 2011
    Assignee: Bayer Schering Pharma AG
    Inventors: Ulrich Luecking, Duy Nguyen, Arne von Bonin, Oliver von Ahsen, Gerhard Siemeister, Rolf Jautelat, Wolf-Dietrich Doecke
  • Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments
    Patent number: 7750000
    Abstract: The invention relates to novel inhibitors of kinases, and pharmaceutical compositions comprising them. The inhibitors are substituted imidazo[1,2b]pyridazines.
    Type: Grant
    Filed: September 1, 2006
    Date of Patent: July 6, 2010
    Assignee: Bayer Schering Pharma AG
    Inventors: Olaf Prien, Stuart James Ince, Knut Eis, Christoph Huwe, Ulrich Lücking, Rolf Jautelat, Ulrich Zügel, Judith Günther, Benjamin Bader, Manfred Husemann, Karina Schuck
  • SULFOXIMINE-SUBSTITUTED PYRIMIDINES AS CDK- AND/OR VEGF INHIBITORS, THEIR PRODUCTION AND USE AS PHARMACEUTICAL AGENTS
    Publication number: 20100076000
    Abstract: This invention relates to pyrimidine derivatives of general formula I in which Q, R1, R2, R3, R4, R5, X, and m have the meanings that are contained in the description, as inhibitors of cyclin-dependent kinases and VEGF-receptor tyrosine kinases, their production as well as their use as medications for treatment of various diseases.
    Type: Application
    Filed: October 12, 2004
    Publication date: March 25, 2010
    Inventors: Ulrich Lücking, Martin Krüger, Rolf Jautelat, Gerhard Siemeister
  • CDK-inhibitory pyrimidines, their production and use as pharmaceutical agents
    Patent number: 7598260
    Abstract: This invention relates to pyrimidine derivatives of general formula I in which R1, R2, X, A and B have the meanings that are contained in the description, as inhibitors of the cyclin-dependent kinases, their production as well as their use as medications for treating various diseases.
    Type: Grant
    Filed: June 26, 2007
    Date of Patent: October 6, 2009
    Assignee: Bayer Schering Pharma Aktiengesellschaft
    Inventors: Thomas Brumby, Rolf Jautelat, Olaf Prien, Martina Schäfer, Gerhard Siemeister, Ulrich Lücking, Christoph Huwe
  • 17?-alkyl-17?-oxy-estratrienes and intermediate products for their production, use of the 17?-alkyl-17?-oxy-estratrienes for the production of pharmaceutical agents as well as pharmaceutical preparations
    Patent number: 7538100
    Abstract: The invention relates to 17?-alkyl-17?-oxy-estra-1,3,5(10)-trienes that have an antiestrogenic action with general formula I. In addition, the invention also relates to 17-oxo-estra-1,3,5(10)-trienes as well as 17?-hydroxy-estra-1,3,5(10)-trienes as intermediate products in the production of the estratrienes according to the invention. The invention also relates to the use of 17?-alkyl-17?-oxy-estratrienes for the production of pharmaceutical agents as well as pharmaceutical preparations that contain at least one 17?-alkyl-17?-oxy-estratriene as well as at least one pharmaceutically compatible vehicle.
    Type: Grant
    Filed: July 26, 2005
    Date of Patent: May 26, 2009
    Assignee: Bayer Schering Pharma Aktiengesellschaft
    Inventors: Rolf Bohlmann, Nikolaus Heinrich, Rolf Jautelat, Jorg Kroll, Orlin Petrov, Andreas Reichel, Jens Hoffmann, Rosemarie Lichtner
  • N-Aryl-sulfoximine-substituted pyrimidines as CDK-and/or VEGF inhibitors, their production and use as pharmaceutical agents
    Patent number: 7456191
    Abstract: This invention relates to pyrimidine derivatives of general formula (I) in which Q, R1, R2, R3, R4, R5, X, and m have the meanings that are contained in the description, as inhibitors of cyclin-dependent kinases and VEGF-receptor tyrosine kinases, their production as well as their use as medications for treatment of various diseases.
    Type: Grant
    Filed: March 22, 2006
    Date of Patent: November 25, 2008
    Assignee: Schering AG
    Inventors: Ulrich Luecking, Gerhard Siemeister, Rolf Jautelat
  • NOVEL HETARYL-PHENYLENEDIAMINE-PYRIMIDINES AS PROTEIN KINASE INHIBITORS
    Publication number: 20080176866
    Abstract: The invention relates to novel hetaryl-phenylenediamine-pyrimidines and to their structurally related oxygen and sulphur analogues of the general formula I, processes for their preparation, and their use as medicaments.
    Type: Application
    Filed: December 19, 2007
    Publication date: July 24, 2008
    Inventors: Rolf Jautelat, Gerhard Siemeister, Ulrich Luecking
  • Carbamoylsulphoximides as protein kinase inhibitors
    Publication number: 20080167330
    Abstract: The invention relates to carbamoylsulphoximides as protein kinase inhibitors of the general formula 1.
    Type: Application
    Filed: August 28, 2007
    Publication date: July 10, 2008
    Inventors: Ulrich Luecking, Gerhard Siemeister, Rolf Jautelat
  • SULPHIMIDES AS PROTEIN KINASE INHIBITORS
    Publication number: 20080058358
    Abstract: The invention relates to sulphimides as protein kinase inhibitors of the general formula I
    Type: Application
    Filed: June 7, 2007
    Publication date: March 6, 2008
    Inventors: Ulrich Luecking, Duy Nguyen, Arne von Bonin, Oliver von Ahsen, Gerhard Siemeister, Rolf Jautelat, Wolf-Dietrich Doecke
  • Sulfoximine-substituted pyrimidines as CDK-and/or VEGF inhibitors, their production and use as pharmaceutical agents
    Patent number: 7338958
    Abstract: This invention relates to pyrimidine derivatives of general formula I in which Q, R1, R2, R3, R4, R5, X, and m have the meanings that are contained in the description, as inhibitors of cyclin-dependent kinases and VEGF-receptor tyrosine kinases, their production as well as their use as medications for treatment of various diseases.
    Type: Grant
    Filed: October 18, 2004
    Date of Patent: March 4, 2008
    Assignee: Schering AG
    Inventors: Ulrich Luecking, Gerhard Siemeister, Martin Krueger, Rolf Jautelat
  • CDK-Inhibitory pyrimidines, their production and use as pharmaceutical agents
    Publication number: 20080039447
    Abstract: This invention relates to pyrimidine derivatives of general formula I in which R1, R2, X, A and B have the meanings that are contained in the description, as inhibitors of the cyclin-dependent kinases, their production as well as their use as medications for treating various diseases.
    Type: Application
    Filed: June 26, 2007
    Publication date: February 14, 2008
    Inventors: Thomas Brumby, Rolf Jautelat, Olaf Prien, Martina Schafer, Gerhard Siemeister, Ulrich Lucking, Christoph Huwe